Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTIER: Nerinetide in Acute Cerebral Ischemia
NCT02315443Phase 3Completed
- Sponsor
- NoNO Inc.
- Start
- Mar 2015
- Primary completion
- Mar 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute cerebral ischemia comparing Nerinetide with Placebo (2 arms). Primary endpoint: Modified Rankin Scale at 90 days. Started Mar 2015; status: completed.
02
Drugs
nerinetide
03
Conditions
acute cerebral ischemia
Beyond the preview
Go deeper on NCT02315443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315443.